Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315) announced that the Japan Patent Office (JPO) has granted an invention patent for the key technology of its independently developed RenMab fully human antibody mouse platform. This milestone strengthens the global intellectual property portfolio of the RenMice fully human antibody platform family and underscores the international recognition of the company's proprietary technologies.
Revolutionary Platform Technology
RenMab mice represent a core component of Biocytogen's independently developed RenMice fully human antibody discovery platform family. The platform utilizes Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE) technology to precisely replace the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes in situ with their human counterparts.
This engineering approach enables RenMab mice to possess the full repertoire of human antibody heavy chain VDJ and light chain VJ genes while retaining the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice. The platform can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates.
Streamlined Development Process
A key advantage of the RenMab platform is that antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process. This eliminates a traditionally time-consuming and costly step in therapeutic antibody development.
The RenMice platform series, which includes RenMab, RenLite, RenNano, RenTCR-mimic, and RenTCR variants, offers distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties.
Extensive Industry Partnerships
The platform has gained widespread recognition in the global biotech and biopharmaceutical industry, with licensing agreements established with more than 20 companies, including major pharmaceutical players such as Merck KGaA (Darmstadt, Germany), Janssen/Johnson & Johnson, and BeiGene.
Leveraging the RenMice platform, Biocytogen's RenBiologics program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the platform's strong global competitiveness and significant commercial value.
Expanding Global Patent Portfolio
Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice platform through sustained independent research and cutting-edge technological innovation capabilities. The RenMice platform has secured patent grants in nearly 10 countries, including the United States, China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions.
With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide.
Company Overview
Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice platforms for fully human monoclonal, bispecific, and multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery, and TCR-mimic antibody discovery. The company has established over 50 target-nominated RenMice licensing projects globally, including several partnerships with multinational pharmaceutical companies.
Headquartered in Beijing, Biocytogen operates branches in China (Haimen Jiangsu, Shanghai), the United States (Boston, San Francisco, San Diego), and Germany (Heidelberg), positioning itself as a global biotechnology company driving the research and development of novel antibody-based drugs.
